FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295819832> ?p ?o ?g. }

• W4295819832 endingPage "S878" @default.
• W4295819832 startingPage "S877" @default.
• W4295819832 abstract "ICT01, an anti-BTN3A mAb, activates γ9δ2 T cells that orchestrate a robust antitumor immune response of the innate and adaptive immune systems that leads to solid tumor infiltration of γ9δ2 T cells, CD8 T cells, and NK cells. (ESMO 2021, #9580) This immune-remodeling by ICT01 when combined with pembrolizumab unleashes the newly-activated, PD-1 expressing γ9δ2 and CD8 T cells that provide a novel, complementary combination immunotherapy regimen for CPI-failure patients that remain a large unmet medical need. In the combination arm of the EVICTION Trial, patients with advanced, metastatic melanoma, bladder cancer, or NSCLC who failed ≥1 prior CPI were treated with ICT01 plus pembrolizumab (200 mg IV Q3W). i/RECIST was conducted every 8 weeks for efficacy (1° Disease Control Rate (DCR) and 2° Overall Response Rate (ORR)) in evaluable patients (recieved 3 cycles and had a Wk 8 i/RECIST). Blood samples were collected for ICT01 target occupancy, immunophenotyping and cytokine analysis (IFNg, TNFa, IL-1b/2/4/6/8/10/12/13). Tumor biopsies (baseline, Day 28) were used for IHC of BTN3A and tumor-infiltrating lymphocytes, and gene expression profiling. Overall, ICT01 + pembro was considered safe and well-tolerated across a range of ICT01 doses (700 mcg - 200 mg, n=36), without any DLTs. Activation & migration of all circulating γ9δ2 T cells was observed 30 min post dose that returned to baseline only at doses ≤7 mg. NK and CD8 T cell activation and margination was observed 24h post dose at doses of ICT01 ≥ 7 or ≥ 20 mg, respectively. 10- to 100-fold increases in IFNγ, TNFα and CXCL10 were observed for 24h post dose. Intra-tumoral γδ, CD3, CD3+Ki67+, CD8 and CD8+ Ki67+ cell densities increased as did gene signatures for intratumoral inflammation (ImmunoSign21, IFNγ response, T cell activation). Efficacy Evaluable (n=24): 6 Melanoma: 50% DCR, 33% ORR; 11 NSCLC: 36% DCR, 9% ORR; 6 Bladder: 33% DCR, 17% ORR. The 3 melanoma responders were IPI/Nivo refractory, with 2 PRs achieved at 2 & 20 mg in pts with high baseline γ9δ2 T cell counts. ICT01 plus pembro is a novel immunotherapeutic approach worth further study in CPI failure pts." @default.
• W4295819832 created "2022-09-15" @default.
• W4295819832 creator A5001906020 @default.
• W4295819832 creator A5003393586 @default.
• W4295819832 creator A5025270017 @default.
• W4295819832 creator A5025753084 @default.
• W4295819832 creator A5030523847 @default.
• W4295819832 creator A5034434819 @default.
• W4295819832 creator A5042693936 @default.
• W4295819832 creator A5043465042 @default.
• W4295819832 creator A5057407696 @default.
• W4295819832 creator A5060793722 @default.
• W4295819832 creator A5065206480 @default.
• W4295819832 creator A5065649723 @default.
• W4295819832 creator A5070026829 @default.
• W4295819832 creator A5071309752 @default.
• W4295819832 creator A5072465879 @default.
• W4295819832 creator A5073195543 @default.
• W4295819832 creator A5073956098 @default.
• W4295819832 creator A5076358850 @default.
• W4295819832 creator A5089500600 @default.
• W4295819832 creator A5089622240 @default.
• W4295819832 date "2022-09-01" @default.
• W4295819832 modified "2023-09-27" @default.
• W4295819832 title "732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial" @default.
• W4295819832 doi "https://doi.org/10.1016/j.annonc.2022.07.858" @default.
• W4295819832 hasPublicationYear "2022" @default.
• W4295819832 type Work @default.
• W4295819832 citedByCount "0" @default.
• W4295819832 crossrefType "journal-article" @default.
• W4295819832 hasAuthorship W4295819832A5001906020 @default.
• W4295819832 hasAuthorship W4295819832A5003393586 @default.
• W4295819832 hasAuthorship W4295819832A5025270017 @default.
• W4295819832 hasAuthorship W4295819832A5025753084 @default.
• W4295819832 hasAuthorship W4295819832A5030523847 @default.
• W4295819832 hasAuthorship W4295819832A5034434819 @default.
• W4295819832 hasAuthorship W4295819832A5042693936 @default.
• W4295819832 hasAuthorship W4295819832A5043465042 @default.
• W4295819832 hasAuthorship W4295819832A5057407696 @default.
• W4295819832 hasAuthorship W4295819832A5060793722 @default.
• W4295819832 hasAuthorship W4295819832A5065206480 @default.
• W4295819832 hasAuthorship W4295819832A5065649723 @default.
• W4295819832 hasAuthorship W4295819832A5070026829 @default.
• W4295819832 hasAuthorship W4295819832A5071309752 @default.
• W4295819832 hasAuthorship W4295819832A5072465879 @default.
• W4295819832 hasAuthorship W4295819832A5073195543 @default.
• W4295819832 hasAuthorship W4295819832A5073956098 @default.
• W4295819832 hasAuthorship W4295819832A5076358850 @default.
• W4295819832 hasAuthorship W4295819832A5089500600 @default.
• W4295819832 hasAuthorship W4295819832A5089622240 @default.
• W4295819832 hasBestOaLocation W42958198321 @default.
• W4295819832 hasConcept C126322002 @default.
• W4295819832 hasConcept C143998085 @default.
• W4295819832 hasConcept C167672396 @default.
• W4295819832 hasConcept C203014093 @default.
• W4295819832 hasConcept C2777701055 @default.
• W4295819832 hasConcept C2778326572 @default.
• W4295819832 hasConcept C2778822529 @default.
• W4295819832 hasConcept C2779134260 @default.
• W4295819832 hasConcept C2779984678 @default.
• W4295819832 hasConcept C2780057760 @default.
• W4295819832 hasConcept C71924100 @default.
• W4295819832 hasConcept C8891405 @default.
• W4295819832 hasConceptScore W4295819832C126322002 @default.
• W4295819832 hasConceptScore W4295819832C143998085 @default.
• W4295819832 hasConceptScore W4295819832C167672396 @default.
• W4295819832 hasConceptScore W4295819832C203014093 @default.
• W4295819832 hasConceptScore W4295819832C2777701055 @default.
• W4295819832 hasConceptScore W4295819832C2778326572 @default.
• W4295819832 hasConceptScore W4295819832C2778822529 @default.
• W4295819832 hasConceptScore W4295819832C2779134260 @default.
• W4295819832 hasConceptScore W4295819832C2779984678 @default.
• W4295819832 hasConceptScore W4295819832C2780057760 @default.
• W4295819832 hasConceptScore W4295819832C71924100 @default.
• W4295819832 hasConceptScore W4295819832C8891405 @default.
• W4295819832 hasLocation W42958198321 @default.
• W4295819832 hasOpenAccess W4295819832 @default.
• W4295819832 hasPrimaryLocation W42958198321 @default.
• W4295819832 hasRelatedWork W1996150995 @default.
• W4295819832 hasRelatedWork W2738397398 @default.
• W4295819832 hasRelatedWork W2777867648 @default.
• W4295819832 hasRelatedWork W2786497694 @default.
• W4295819832 hasRelatedWork W2916953213 @default.
• W4295819832 hasRelatedWork W3153432702 @default.
• W4295819832 hasRelatedWork W3156977102 @default.
• W4295819832 hasRelatedWork W3161613553 @default.
• W4295819832 hasRelatedWork W3215044659 @default.
• W4295819832 hasRelatedWork W4206362823 @default.
• W4295819832 hasVolume "33" @default.
• W4295819832 isParatext "false" @default.
• W4295819832 isRetracted "false" @default.
• W4295819832 workType "article" @default.